Results 251 to 260 of about 4,312,195 (323)

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

Tofacitinib extends survival in a mouse model of ALS through NK cell-independent mechanisms. [PDF]

Front Immunol
Baird LA, Teener SJ, Webber-Davis IF, Carter AD, Huang F, Jang DG, Famie JP, Piecuch CE, Guo K, Feldman EL, Murdock BJ.   +10 more
europepmc   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

The cGAS-STING Pathway in Dementia: An Emerging Mechanism of Neuroinflammation. [PDF]

Brain Sci
Min Y, Lee YS, Lee J, Keum DY, Gwag JY, Jeon SM, Jo H, Kang SU.   +7 more
europepmc   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

Mapping the developmental path for Parkinson's disease therapeutics. [PDF]

NPJ Parkinsons Dis
Dhruv NT, Robinson Schwartz S, Swanson-Fischer C, Cho HJ, Corlew R, Jakeman L, Laboissonniere LA, Price R, Sarraf S, Sieber BA, Torborg C, Wonders C, Chen-Plotkin A, Martin WJ, Tamiz AP.   +14 more
europepmc   +1 more source

Association among blood pressure, antihypertensive drugs, and amyotrophic lateral sclerosis. [PDF]

Arq Neuropsiquiatr
Li Z, Li Y, Zhao J, Zhang F, Dang W, Jia Y, Guo F, Guo L.   +7 more
europepmc   +1 more source

[Renewed increase in new Janus kinase inhibitor prescriptions : Analysis of the German RHADAR registry]. [PDF]

Z Rheumatol
Strunz PP, Risser LM, Englbrecht M, Witte T, Fröhlich M, Schmalzing M, Gernert M, Heck J, Bartz-Bazzanella P, von der Decken C, Karberg K, Gauler G, Späthling-Mestekemper S, Kuhn C, Vorbrüggen W, Welcker M, Kleinert S.   +16 more
europepmc   +1 more source

Cathepsins in Neurological Diseases. [PDF]

Int J Mol Sci
Lewandowski D, Konieczny M, Różycka A, Chrzanowski K, Owecki W, Kalinowski J, Stepura M, Jagodziński P, Dorszewska J.   +8 more
europepmc   +1 more source